Avastin improves survival rates in patients affected by recurrent glioblastomaThe targeted therapy Avastin, in a combination or isolation, has the capability of considerably increasing response rates, survival rates, and progression-free survival times in patients suffering from recurrent glioblastoma, a deadly form of brain cancer.

Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study, remarked that Avastin alone and Avastin given with CPT-11 can improve the response rate and overall survival to a considerable extent.

Cloughesy remarked that the findings of this study constitute a huge breakthrough as Avastin has proved itself to be of great usefulness for treating patients with recurrent glioblastoma. It was also remarked that Avastin brings the level of brain swelling down and can even help in reducing the doses of steroids to ensure marked improvement in function.